CLAIMS

1. A muscle atrophy inhibitor comprising a quercetin glycoside.

2. The muscle atrophy inhibitor according to claim 1, wherein inhibition of muscle atrophy is triggered by inhibition of Mstn expression.

3. The muscle atrophy inhibitor according to claim 1 or 2, wherein inhibition of muscle atrophy is triggered by inhibition of the expression of at least one gene selected from the group consisting of Atrogin-1, MuRF-1, Foxo1 and Redd1.

4. The muscle atrophy inhibitor according to any one of claims 1 to 3, wherein the muscle atrophy inhibitor has muscle degradation inhibitory activity.

5. The muscle atrophy inhibitor according to claim 4, wherein the muscle degradation inhibitory activity is triggered by inhibition of the expression of at least one gene selected from the group consisting of Atrogin-1, MuRF-1 and Foxo1.

6. The muscle atrophy inhibitor according to any one of claims 1 to 3, wherein the muscle atrophy inhibitor has muscle synthesis stimulatory activity.

7. The muscle atrophy inhibitor according to claim 6, wherein the muscle synthesis stimulatory activity is triggered by inhibition of the expression of Redd1.

8. The muscle atrophy inhibitor according to any one of claims 1 to 7, wherein the muscle atrophy inhibitor is intended for use in the prevention or treatment of impaired motor functions or motor disorders.

9. The muscle atrophy inhibitor according to any one of claims 1 to 7, wherein the muscle atrophy inhibitor is intended for use in the prevention or treatment of drug-induced muscle atrophy.

10. A composition comprising the muscle atrophy inhibitor according to any one of claims 1 to 9.

CLAIMS

1. Use of a quercetin glycoside in the preparation of a composition for inhibiting expression of Mstn.

2. Use of a quercetin glycoside in the preparation of a composition for inhibiting expression of at least one gene selected from Atrogin-1, MuRF-1, Foxo 1, or Redd 1.

3. The use according to claim 1 or 2, wherein the composition inhibits muscle atrophy.

4. The use according to claim 1 or 2, wherein the composition inhibits muscle degradation.

5. The use according to claim 1 or 2, wherein the composition stimulates muscle synthesis.

6. The use according to claim 1 or 2, wherein the composition prevents or treats impaired motor functions or motor disorders.

7. The use according to claim 1 or 2, wherein the composition prevents or treats drug-induced muscle atrophy.

8. The use according to any one of claims 1 to 7, wherein the quercetin glycoside is a mixture of quercetin glycosides having a sugar chain consisting of one to seven glucoses.